Research · enforcement tracker

Supplement claims enforcement, dated and sourced.

A public record of what regulators and marketplaces actually did about supplement marketing claims, and which standard each action maps to. Every entry carries a date and a source. Nothing here is a prediction.

The record in numbers

Entries on the record
39
Live feed entries
36
FDA 17 · FTC 4 · NAD/NARB 15
Feeds checked
25 SEP 2026

Newest entry listed · 17 SEP 2026 · FDA warning letters post weekly, one to three weeks after issue.

What this tracker is

The record the standards move with.

Our standards are admitted, not invented: a phrase enters the standards because a regulator, a marketplace or a court moved first. This page is that source record, kept in public so anyone can check the reasoning, cite the date, and see when the ground shifted under a claim they are still running.

Two kinds of entry. The dated events below are checked against their source and restated in one plain sentence each. The rest are pulled straight from three public records each week and listed exactly as published, with the date, the wording the body used, and a link to the action itself: FDA warning letters, FTC consumer-protection actions on health claims, and National Advertising Division and NARB decisions, which rule on advertising claims rather than statute.

The record, newest first

Every action, with the standard it maps to.

17 SEP 2026
FTC action · Multilevel Marketing Operator Amway

The Federal Trade Commission published this action. Headline as published: FTC Takes Historic Action Against Multilevel Marketing Operator Amway for Unfair and Deceptive Business Practices.

FTC press release →
RULEBOOK 02 · FTCSubstantiation standards
17 SEP 2026
NAD decision · Starkey Laboratories

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Starkey Laboratories Modify or Discontinue Certain Omega AI Hearing Aid Claims.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
16 SEP 2026
NAD decision · Alice Mushrooms

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Qualified Saffron Claim Supported; Recommends Alice Mushrooms Discontinue Zen-X Health Claim.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
24 AUG 2026
FDA warning letter · BioDrive, Inc.

The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/Adulterated.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
24 AUG 2026
NAD decision · Hims & Hers Health

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other Claims.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
31 JUL 2026
FDA warning letter · H2 BEV, LLC and H2 RENU, INC

The FDA posted a warning letter to this company. Subject as published: Acidified Foods/Emergency Permit Control/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
Show all 39 entriesShow fewer
24 JUL 2026
NAD decision · Willow Health

The National Advertising Division ruled on this advertiser’s claims. Decision as published: Following Reopened National Advertising Division Matter, Willow Health Services Voluntarily Discontinues Claims for Compounded Semaglutide Products.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
15 JUL 2026
FTC action · TruHeight

The Federal Trade Commission published this action. Headline as published: FTC Approves Final Order Against TruHeight for Deceptive and Unsubstantiated Advertising of Supplements for Kids and Teens.

FTC press release →
RULEBOOK 02 · FTCSubstantiation standards
09 JUL 2026
FDA warning letter · VasoCorp, Inc.

The FDA posted a warning letter to this company. Subject as published: Unapproved New Drugs/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
12 JUN 2026
FTC action · Amare Global

The Federal Trade Commission published this action. Headline as published: FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims.

FTC press release →
RULEBOOK 02 · FTCSubstantiation standards
05 JUN 2026
FDA warning letter · Mineral BioSciences, LLC

The FDA posted a warning letter to this company. Subject as published: Unapproved New Drugs/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
05 JUN 2026
FDA warning letter · Imu-Tek Animal Health, Incorporated

The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
04 JUN 2026
FDA warning letter · Nutratech, LLC

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
02 JUN 2026
FTC action · Amare Global Holdings

The Federal Trade Commission published this action. Headline as published: FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements for Children and Adults.

FTC press release →
RULEBOOK 02 · FTCSubstantiation standards
26 MAY 2026
NAD decision · Noom

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Noom Modify or Discontinue “A Smaller Dose. A Smarter Start” Claim for Microdose GLP-1RX Program.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
21 MAY 2026
NARB decision · Niagen

The National Advertising Review Board ruled on this advertiser’s claims. Decision as published: National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims.

BBB National Programs, National Advertising Review Board →
SELF-REGULATORY · NARBAdvertising substantiation standards
20 MAY 2026
NARB decision · Merck Animal Health Bravecto® Quantum

The National Advertising Review Board ruled on this advertiser’s claims. Decision as published: National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims.

BBB National Programs, National Advertising Review Board →
SELF-REGULATORY · NARBAdvertising substantiation standards
15 MAY 2026
FDA warning letter · Meta Labs Pharmaceuticals, LLC

The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
12 MAY 2026
FDA warning letter · Flax & More Corporation

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
29 APR 2026
FDA warning letter · OptiHealth Products, Inc.

The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
27 APR 2026
NAD decision · Nature’s Truth

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Nature’s Truth Modify or Discontinue Certain Magnesium Claims for Magnesium Glycinate Gummies.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
07 APR 2026
FDA warning letter · Nature’s Elements, Inc.

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
MAR 2026
The Supplement Facts panel match, as reported

Trade press reported that from 31 March 2026 Amazon began requiring detail-page content to align with the Supplement Facts panel, enforced automatically. Amazon has not published the policy itself, so this is reported rather than official.

TRADE PRESS · AMAZONPlatform-policy standardsSource · NutraIngredients, 13 Mar 2026
31 MAR 2026
NAD decision · Bayer

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men’s Pre-Conception Health Complete Multivitamin Claims.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
30 MAR 2026
NAD decision · Iron Rock

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Refers Iron Rock NAD+ Dietary Supplement Claims to Regulatory Authorities.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
24 MAR 2026
NAD decision · Viome

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Certain CancerDetect® Claims Supported; Recommends Viome Modify or Discontinue Others.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
16 MAR 2026
NAD decision · Niagen

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Claims; Niagen to Appeal.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
02 MAR 2026
NAD decision · OLLY

The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends OLLY Modify “Calm & Relaxed” Claims for Kids Chillax Supplement.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
25 FEB 2026
NAD decision · Midi Health

The National Advertising Division ruled on this advertiser’s claims. Decision as published: In National Advertising Division Challenge, Midi Health Permanently Discontinues Challenged Claims for Menopause Care Services.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
23 JAN 2026
FDA warning letter · Intelligent Remedies, Inc.

The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
22 JAN 2026
FDA warning letter · Diamond-Herpanacine of PA, Inc.

The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
21 JAN 2026
FDA warning letter · Supersmart USA, LLC

The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
23 DEC 2025
FDA warning letter · LXR Biotech, LLC

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
11 DEC 2025
NAD decision · Asutra

The National Advertising Division ruled on this advertiser’s claims. Decision as published: In National Advertising Division Challenge, Asutra Voluntarily Discontinues Claims for Magnesium Body Butter with Capsaicin.

BBB National Programs, National Advertising Division →
SELF-REGULATORY · NADAdvertising substantiation standards
18 SEP 2025
FDA warning letter · Time Challenger Labs International, Inc.

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
10 SEP 2025
FDA warning letter · Eniva USA, Inc.

The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
25 JUN 2025
FDA warning letter · Royal Diamond Imports, Inc.

The FDA posted a warning letter to this company. Subject as published: Unapproved New Drug/Misbranded.

FDA warning-letter database →
RULEBOOK 01 · FDAFDA claim standards
APR 2023
FTC puts about 670 marketers on penalty notice

Supplement, over-the-counter and functional-food marketers received a formal Notice of Penalty Offenses, which exposes unsubstantiated claims to civil penalties of $53,088 per violation under the statutory schedule.

Penalty figure: 16 CFR 1.98(d), 90 FR 5581 (17 Jan 2025); event: FTC Notice of Penalty Offenses distribution, Apr 2023 →
RULEBOOK 02 · FTCSubstantiation standards
2023
JAMA finds 88% of melatonin gummies mislabelled

A peer-reviewed analysis found 88% of tested melatonin gummy products were mislabelled, with measured doses running from 74% to 347% of the amount stated on the label.

EVIDENCE · PEER-REVIEWEDSubstantiation standardsSource · JAMA, 2023

Dates are the source’s own. Where a source gives only a month or a year, that is what we print.

What to do with it

Three ways brands use this page.

01Check your copy

Read the entry, then read your listing. If an action names a claim family you are running, a regulator has already ruled against that wording somewhere. The claim rulings say what to write instead.

02Answer a letter

A warning letter starts a 15-business-day clock. The claims half of the reply is what we build: see warning-letter response.

03Cite it

Journalists, analysts and counsel are free to quote this record with attribution. The aggregate compliance data sits on the research page.

Cite usJournalists and researchers: this tracker is free to use. Credit “Claims Verified” and link here. Want to know how an entry was checked, or think we have one wrong? Email the research team directly and we will correct it.

audit@claimsverified.org →

Find out whether any of this is about you.

Run one ASIN through the free check and see the severity counts on your own listing, ruled against the same 98 standards this record feeds.

Free ASIN check